Literature DB >> 26566712

Optimizing psychosocial support during office-based buprenorphine treatment in primary care: Patients' experiences and preferences.

Aaron D Fox1,2, Mariya Masyukova1, Chinazo O Cunningham1,2.   

Abstract

BACKGROUND: Buprenorphine maintenance treatment is effective and has been successfully integrated into human immunodeficiency virus (HIV) and primary care settings. However, one key barrier to providers prescribing buprenorphine is their perception that they are unable to provide adequate counseling or psychosocial support to patients with opioid addiction. This qualitative study investigated supportive elements of office-based buprenorphine treatment that patients perceived to be most valuable.
METHODS: The authors conducted five focus groups with 33 buprenorphine treatment-experienced participants. Focus groups were audio-recorded and transcribed. Iterative readings of transcripts and grounded theory analysis revealed common themes.
RESULTS: Overall, participants perceived that buprenorphine treatment helped them to achieve their treatment goals and valued the flexibility, accessibility, and privacy of treatment. Participants identified interpersonal and structural elements of buprenorphine treatment that provided psychosocial support. Participants desired good physician-patient relationships, but also valued care delivery models that were patient-centered, created a safe place for self-disclosure, and utilized coordinated team-based care.
CONCLUSIONS: Participants derived psychosocial support from their prescribing physician, but were also open to collaborative or team-based models of care, as long as they were voluntary and confidential. Buprenorphine-prescribing physicians without access to referral options for psychosocial counseling could focus on maintaining nonjudgmental attitudes and shared decision-making during patient encounters. Adding structure and psychosocial support to buprenorphine treatment through coordinated team-based care also seems to have great promise.

Entities:  

Keywords:  Buprenorphine; opiate addiction; psychosocial support

Mesh:

Substances:

Year:  2015        PMID: 26566712      PMCID: PMC4801741          DOI: 10.1080/08897077.2015.1088496

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  20 in total

1.  HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.

Authors:  George E Woody; Douglas Bruce; P Todd Korthuis; Sumedha Chhatre; Sabrina Poole; Maureen Hillhouse; Petra Jacobs; James Sorensen; Andrew J Saxon; David Metzger; Walter Ling
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

2.  Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients.

Authors:  Jeanette M Tetrault; Brent A Moore; Declan T Barry; Patrick G O'Connor; Richard Schottenfeld; David A Fiellin; Lynn E Fiellin
Journal:  J Subst Abuse Treat       Date:  2012-08-29

3.  Brief report: Training internists in shared decision making about chronic opioid treatment for noncancer pain.

Authors:  Mark D Sullivan; Janis Leigh; Barak Gaster
Journal:  J Gen Intern Med       Date:  2006-04       Impact factor: 5.128

4.  Barriers to primary care physicians prescribing buprenorphine.

Authors:  Eliza Hutchinson; Mary Catlin; C Holly A Andrilla; Laura-Mae Baldwin; Roger A Rosenblatt
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

5.  "It takes your heart": the image of methadone maintenance in the addict world and its effect on recruitment into treatment.

Authors:  D E Hunt; D S Lipton; D S Goldsmith; D L Strug; B Spunt
Journal:  Int J Addict       Date:  1985 Nov-Dec

6.  Drug poisoning deaths in the United States, 1980-2008.

Authors:  Margaret Warner; Li Hui Chen; Diane M Makuc; Robert N Anderson; Arialdi M Miniño
Journal:  NCHS Data Brief       Date:  2011-12

7.  Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.

Authors:  Wendy Kissin; Caroline McLeod; Joseph Sonnefeld; Arlene Stanton
Journal:  J Addict Dis       Date:  2006

8.  Comparison of behavioral treatment conditions in buprenorphine maintenance.

Authors:  Walter Ling; Maureen Hillhouse; Alfonso Ang; Jessica Jenkins; Jacqueline Fahey
Journal:  Addiction       Date:  2013-07-12       Impact factor: 6.526

9.  A buprenorphine education and training program for primary care residents: implementation and evaluation.

Authors:  Hillary V Kunins; Nancy L Sohler; Angela Giovanniello; Devin Thompson; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2013       Impact factor: 3.716

Review 10.  The potential for motivational interviewing to improve outcomes in the management of diabetes and obesity in paediatric and adult populations: a clinical review.

Authors:  D Christie; S Channon
Journal:  Diabetes Obes Metab       Date:  2013-09-01       Impact factor: 6.577

View more
  14 in total

1.  Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.

Authors:  Richard A Rawson; Traci Rieckmann; Sarah Cousins; Michael McCann; Regina Pearce
Journal:  Prev Med       Date:  2019-07-27       Impact factor: 4.018

Review 2.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Authors:  Kathleen M Carroll; Roger D Weiss
Journal:  Am J Psychiatry       Date:  2016-12-16       Impact factor: 18.112

3.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

4.  Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.

Authors:  Julia R Benville; Peggy Compton; Nicholas A Giordano; Martin D Cheatle
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.492

5.  Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Hannah K Knudsen
Journal:  Addict Behav       Date:  2019-01-16       Impact factor: 4.591

6.  The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial.

Authors:  Lauren K Whiteside; Ly Huynh; Sophie Morse; Jane Hall; William Meurer; Caleb J Banta-Green; Hannah Scheuer; Rebecca Cunningham; Mark McGovern; Douglas F Zatzick
Journal:  J Subst Abuse Treat       Date:  2021-11-24

7.  Mental Health and Psychosocial Needs of Patients Being Treated for Opioid Use Disorder in a Primary Care Residency Clinic.

Authors:  Stephanie A Hooker; Michelle D Sherman; Mary Lonergan-Cullum; Adam Sattler; Bruce S Liese; Kathryn Justesen; Tanner Nissly; Robert Levy
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

8.  Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review.

Authors:  Kirsten Marchand; Scott Beaumont; Jordan Westfall; Scott MacDonald; Scott Harrison; David C Marsh; Martin T Schechter; Eugenia Oviedo-Joekes
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-09-11

Review 9.  Identification and Management of Opioid Use Disorder in Primary Care: an Update.

Authors:  Joseph H Donroe; Elenore P Bhatraju; Judith I Tsui; E Jennifer Edelman
Journal:  Curr Psychiatry Rep       Date:  2020-04-13       Impact factor: 5.285

10.  Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.

Authors:  Kirsten Marchand; Julie Foreman; Scott MacDonald; Scott Harrison; Martin T Schechter; Eugenia Oviedo-Joekes
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.